{"id":"NCT02537574","sponsor":"Alkermes, Inc.","briefTitle":"Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)","officialTitle":"A Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL®","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-08","primaryCompletion":"2016-10-27","completion":"2017-01-09","firstPosted":"2015-09-01","resultsPosted":"2019-01-09","lastUpdate":"2019-03-06"},"enrollment":380,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Opioid Use Disorder"],"interventions":[{"type":"DRUG","name":"NTX/BUP","otherNames":[]},{"type":"DRUG","name":"NTX/PBO-B","otherNames":[]},{"type":"DRUG","name":"PBO-N/PBO-B","otherNames":[]}],"arms":[{"label":"NTX/BUP","type":"EXPERIMENTAL"},{"label":"NTX/PBO-B","type":"ACTIVE_COMPARATOR"},{"label":"PBO-N/PBO-B","type":"PLACEBO_COMPARATOR"}],"summary":"This study will evaluate the safety, effectiveness and tolerance of low doses of oral naltrexone along with buprenorphine to treat opioid use disorder prior to the first injection of VIVITROL.","primaryOutcome":{"measure":"Proportion of Subjects Who Receive and Tolerate a VIVITROL Injection","timeFrame":"1 week","effectByArm":[{"arm":"NTX/BUP","deltaMin":57,"sd":null},{"arm":"NTX/PBO-B","deltaMin":51,"sd":null},{"arm":"PBO-N/PBO-B","deltaMin":57,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.940"},{"comp":"OG001 vs OG002","p":"0.383"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":15},"locations":{"siteCount":20,"countries":["United States"]},"refs":{"pmids":["29674251","34752714"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":126},"commonTop":["Diarrhoea","Anxiety","Nausea"]}}